RVVT.F Stock Overview
A life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Revive Therapeutics Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.0083 |
| 52 Week High | CA$0.036 |
| 52 Week Low | CA$0.0055 |
| Beta | -0.29 |
| 11 Month Change | 25.75% |
| 3 Month Change | -30.42% |
| 1 Year Change | -61.96% |
| 33 Year Change | -98.05% |
| 5 Year Change | -68.24% |
| Change since IPO | -98.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| RVVT.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 7.7% | 3.4% | 1.6% |
| 1Y | -62.0% | 14.2% | 32.3% |
Return vs Industry: RVVT.F underperformed the US Pharmaceuticals industry which returned 13.7% over the past year.
Return vs Market: RVVT.F underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| RVVT.F volatility | |
|---|---|
| RVVT.F Average Weekly Movement | 21.1% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RVVT.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RVVT.F's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Michael Frank | revivethera.com |
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. The company also develops Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; and Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases.
Revive Therapeutics Ltd. Fundamentals Summary
| RVVT.F fundamental statistics | |
|---|---|
| Market cap | US$2.98m |
| Earnings (TTM) | -US$4.01m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs RVVT.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RVVT.F income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$5.62m |
| Earnings | -CA$5.62m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.013 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RVVT.F perform over the long term?
See historical performance and comparison